11/25/2021 | Press release | Distributed by Public on 11/26/2021 00:03
The findings about BA1106, a fully human monoclonal anti-CD25 antibody developed by Boan Biotech, a subsidiary of Luye Pharma Group, were published in Scientific Reports, which is a journal of the Nature Portfolio. Scientific Reports is the sixth most-cited journal in the world, with more than 540,000 citations in 2020.
A screenshot of the paper（Source : Scientific Reports）
CD25, also known as Interleukin-2 receptor alpha (IL-2Rα) chain, is highly expressed on tumor regulatory T cells (Treg cells). Treg cells inhibit a variety of immune cells, which is an important factor in the poor prognosis of most solid tumors. Therefore, eliminating Treg cells in tumor microenvironment becomes an important antitumor immunity strategy.
As one of the specific markers on the surface of Treg cells, CD25 is a potential target for Treg deletion. Taking advantage of the anti-CD25 antibodies' specificity to eliminate Treg cells and inhibit immunosuppression is an important antitumor treatment strategy. However, developing anti-CD25 antibodies faces two major problems at present: First, the mediation function of Fc is limited, and as a result, it only works in early-stage tumor models, but doesn't work in late-stage tumor models; second, the activation of the IL-2R signaling pathway by IL-2 is blocked, leading to poor antitumor performance.
The anti-CD25 antibodies obtained by Boan Biotech have a better efficacy for both early-stage and late-stage tumors, and demonstrate a good synergy when used in combination with an anti-PD1 antibody: they can basically clean up all the established tumors in an MC38 colon cancer model. Meanwhile, they don't block the activation of the IL-2R signaling pathway by IL-2, and have a moderate and specific blocking effect on Treg cells. The detailed findings are as follows:
"Based on the research data obtained till now, we found that BA1106 moderately eliminates Treg cells, and inhibits immunosuppression in tumor microenvironment without blocking the IL-2 signalling pathway, and can be used in combination with anti-PD1, so it is expected to recover the resistance of the current therapy based on anti-PD1 to some extent, and to become a promising antitumor therapy," said Dr. Dou Changlin, the corresponding author of this paper, who is also the President and COO of Boan Biotech. "BA1106 currently leads the way among anti-CD25 antibodies with this acting mechanism," he added. "We believe that, with further development in the future, BA1106 will become another major therapy of Boan Biotech for treating solid tumors, to form a strong portfolio along with our 10+ other innovative antibody candidates."
About Boan Biotech
As a subsidiary of Luye Pharma Group, Boan Biotech is a fully integrated biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization with a focus on oncology, immunology, pain, and endocrine diseases. Boan Biotech's antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform and ADC Technology Platform. The company has developed more than 10 innovative antibody product candidates with international intellectual property protection, and 7 biosimilar product candidates, one of which - Boyounuo (Bevacizumab Injection) - has been launched in China.
Boan Biotech has expertise in the full industry chain: antibody generation, lead optimization, cell line development, process development, technology transfer, pilot and commercial scale production. The company is also actively exploring other cutting-edge technologies. Its cell therapy products use non-viral vectors for CAR-T for late stage solid tumors. Boan Biotech is also exploring novel off-the-shelf CAR-T and regulatable CAR-T, to develop safer, effective and affordable products for patients. Outside of China, Boan Biotech also pursues biopharmaceutical products development in the US and EU markets.